Published in Drug Metab Dispos on September 06, 2006
Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol (2003) 1.86
Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos (2002) 1.45
Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol (2007) 1.25
CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos (2006) 1.24
Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common. Drug Metab Dispos (2007) 1.21
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos (2004) 1.19
Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol (2005) 1.19
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys (2003) 1.11
Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Arch Biochem Biophys (2006) 1.08
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos (2009) 1.07
CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos (2010) 1.06
Your role and responsibilities in the manuscript peer review process. Am J Pharm Educ (2008) 1.05
Social network analysis to assess the impact of the CTSA on biomedical research grant collaboration. Clin Transl Sci (2014) 1.05
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics (2010) 1.03
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin Pharmacol (2003) 1.02
Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry (2004) 1.00
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research. Pharmacotherapy (2008) 0.99
Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos (2009) 0.98
CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol (2005) 0.96
Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos (2004) 0.95
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos (2007) 0.93
Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol (2007) 0.92
Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos (2005) 0.92
Medication use in a rural gynecologic population: prescription, over-the-counter, and herbal medicines. Am J Obstet Gynecol (2004) 0.91
Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther (2006) 0.91
Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos (2002) 0.90
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos (2010) 0.88
Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9. J Am Chem Soc (2006) 0.87
Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos (2006) 0.87
Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode. Drug Metab Dispos (2009) 0.86
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics (2012) 0.84
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry (2008) 0.84
Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab Dispos (2006) 0.84
Measurement of electron transfer through cytochrome P450 protein on nanopillars and the effect of bound substrates. J Am Chem Soc (2013) 0.84
Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos (2010) 0.83
Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol (2004) 0.83
Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos (2008) 0.82
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem (2007) 0.82
Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Arch Biochem Biophys (2008) 0.82
Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos (2008) 0.80
The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites. Appl Biochem Biotechnol (2013) 0.79
Comparison of U.S. and Chinese pharmacy education programs. Am J Health Syst Pharm (2014) 0.78
Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation. Toxicol Appl Pharmacol (2005) 0.78
The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase. Drug Metab Dispos (2011) 0.77
Different enzyme kinetic models. Methods Mol Biol (2014) 0.77
Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecol Oncol (2012) 0.77
Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes. Nanotechnology (2012) 0.77
Nanoscale electron transport measurements of immobilized cytochrome P450 proteins. Nanotechnology (2015) 0.76
Studying cytochrome P450 kinetics in drug metabolism. Expert Opin Drug Metab Toxicol (2008) 0.76
Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9. J Biomol Screen (2006) 0.76
Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator. Drug Metab Dispos (2011) 0.76
Case study 3. Application of basic enzyme kinetics to metabolism studies: real-life examples. Methods Mol Biol (2014) 0.75
Conversion of methamphetamine to N-methyl-methamphetamine in formalin solutions. J Anal Toxicol (2005) 0.75
Fundamentals of enzyme kinetics. Methods Mol Biol (2014) 0.75